Lumos Pharma Stock Forum

$Lumos Pharma (LUMO.US)$
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). The event will take place from October 2-5, 2024, i...

$Lumos Pharma (LUMO.US)$
I'm holding a little. hope gradually 🛫✌️

$Lumos Pharma (LUMO.US)$
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than tradit...

$Lumos Pharma (LUMO.US)$ Reuters· just
Lumos Pharma Inc: Outcome From End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial

$Lumos Pharma (LUMO.US)$ Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
AUSTIN, TX, April 18, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented...

$Lumos Pharma (LUMO.US)$ Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042

$Lumos Pharma (LUMO.US)$ © Reuters. Lumos Pharma (ticker: NASDAQ:LUMO) has announced promising top-line results from its OraGrowtH210 and OraGrowtH212 trials for LUM-201, highlighting its potential as an oral treatment for pediatric growth hormone deficiency (PGHD). The company detailed plans for future trials and regulatory discussions during its recent earnings call. With $36.1 million in cash at the end of 2023, Lumos Pharma is funded through Q3 2024 and is actively exploring partnership...

$Lumos Pharma (LUMO.US)$
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

$Lumos Pharma (LUMO.US)$ 5